Surgical Applications
Clinical Evidence
Surgical Applications

Clinical Evidence

RECOVER I Data After Post-Cardiotomy Cardiogenic Shock1

  • 94%

    survival at 1 month

  • 81%

    survival at 6 months

  • 75%

    survival at 1 year

Hemodynamic parameters improved immediately after Impella 5.0® placement, leading to an increase in mean cardiac index (CI) from 1.4 to 2.5 L/min/m2 and an increase in MAP from 71 mmHg to 83 mmHg.

Ongoing and Upcoming Clinical Trials

STEMI Door-to-Unloading (DTU) Pivotal Randomized Controlled Trial

This trial is randomizing patients undergoing treatment for ST-Elevation Myocardial Infarction (STEMI) who are not in cardiogenic shock to either 30 minutes of unloading with Impella CP® prior to reperfusion or standard of care with immediate PCI. 

Learn More

IMPACT: Impella Protected Cardiac Surgery Trial

This upcoming trial will evaluate the peri-operative use of Impella 5.5® with SmartAssist® in high-risk surgical patients.

Explore Procedural Best Practices

References

  1. Griffith, B.P., et al. (2013). J Thorac Cardiovasc Surg, 145(2), 548-554.

NPS-1195

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].

The Protected PCI community
is now on HeartRecovery.com

Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
Explore Now